Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Operating Expenses (2016 - 2025)

Dare Bioscience's Operating Expenses history spans 11 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 58.7% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $14.3 million, down 39.11%, while the annual FY2025 figure was $14.3 million, 39.11% down from the prior year.
  • Operating Expenses reached $2.2 million in Q4 2025 per DARE's latest filing, down from $3.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.2 million in Q4 2022 to a low of $2.2 million in Q4 2025.
  • Average Operating Expenses over 5 years is $7.6 million, with a median of $7.5 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: surged 80.85% in 2021, then crashed 58.7% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $9.5 million in 2021, then soared by 70.08% to $16.2 million in 2022, then tumbled by 57.0% to $7.0 million in 2023, then dropped by 23.71% to $5.3 million in 2024, then plummeted by 58.7% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Operating Expenses are $2.2 million (Q4 2025), $3.7 million (Q3 2025), and $3.8 million (Q2 2025).